Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Serum Irisin Levels as a Potential Biomarker in Patients With Diabetic Polyneuropathy: A Single-center Prospective Cross-sectional Observational Study

NCT07734597 is registered in ClinicalTrials.gov with GÜLDEN ANATACA as lead sponsor.

NCT NCT07734597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07734597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Serum Irisin Levels as a Potential Biomarker in Patients With Diabetic Polyneuropathy: A Single-center Prospective Cross-sectional Observational Study
Lead sponsor
GÜLDEN ANATACA
Phase
Observational
Overall status
Not yet recruiting
Start date
July 30, 2026
Completion date
September 30, 2026
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2, diabetic complications neurological, polyneuropathies